



4 March 2019

To All New Zealand Pharmacies, Wholesalers

Subject Update - Magnesium sulphate inj 2 mmol per ml, 5 ml ampoule (DBL S29) and Medroxyprogesterone acetate (Provera tab 2.5 mg and 5 mg)

Pages 2

Good afternoon,

Magnesium sulphate inj 2 mmol per ml, 5 ml ampoule

There is currently a supply issue with magnesium sulphate inj 2 mmol per ml, 5 ml ampoule. PHARMAC has been working with the supplier, Pfizer, to manage the stock in the supply chain.

From today, Monday 4 March 2019, Pfizer's DBL S29 brand of magnesium sulphate inj 2 mmol per ml, 5 ml amp will be listed and fully subsidised to ensure sufficient supply of this medicine is available.

The DBL S29 brand of magnesium sulphate is not a registered medicine in New Zealand so will be supplied under section 29 of the Medicines Act 1981. Stat dispensing will apply.

We have been advised by Pfizer that the DBL S29 brand will have the same labelling and packaging as its registered DBL brand (Pharmacode 2213613).

From 4 March 2019 the following will be listing on the Pharmaceutical Schedule:

Chemical	Formulation	Brand	Pack size	Price and subsidy (ex man, excl GST)
Magnesium sulphate (Pharmacode 2563959)	inj 2 mmol per ml, 5 ml ampoule	DBL S29	10	\$10.21

Magnesium sulphate (DBL S29) inj 2 mmol per ml, 5 ml ampoule stock is available from your normal wholesaler.

The Ministry of Health Sector Operations Group will process claims for magnesium sulphate (DBL S29) inj 2 mmol per ml, 5 ml ampoule as per normal.



Pharmacy software instructions:

Instructions for amending your pharmacy software systems are as follows:

RxOne users: this new listing will be automatically updated by RxOne. If for some unforeseen circumstance it does not happen, please refer to the e-Noticeboard on the RxOne Start Menu for instructions.

TONIQ users: the new listing will automatically be updated in Toniq medicine databases from the effective date.

Medroxyprogesterone acetate

Provera tab 2.5 mg (Pharmacode 2536501) and 5 mg (Pharmacode 378135), 56 tab pack were registered with Medsafe in January 2019. These Pharmacodes were listed temporarily to cover an out of stock and will be delisted from August 2019. Pharmacies will now be unable to claim further wastage fees for dispensings of Provera tab 2.5 mg (Pharmacode 2536501) and 5 mg (Pharmacode 378135), 56 tab pack where claims have not yet been submitted for dispensing in January or February 2019.

PHARMAC appreciates the inconvenience this may cause, however, it is our understanding that the impact will be minimal due to the fact that Provera 56 pack is a registered medicine and wastage should not have been claimed.

The original pack sizes 30 tab packs (tab 2.5 mg) and 100 tab packs (tab 5 mg) are now back in stock.

We thank you for your assistance in managing these issues. If you have any questions regarding the above, please contact PHARMAC at enquiry@pharmac.govt.nz or call 0800 660 050.

Kind regards,

A handwritten signature in black ink, appearing to be "LW", followed by a long horizontal flourish.

Lisa Williams
Director of Operations